Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats

Summary

Treatment of diabetic rats with octreotide can inhibit early diabetic renal hypertrophy. Octreotide administration for 6 months from the day of diabetes induction inhibits renal hypertrophy and diminishes increase in urinary albumin excretion. To investigate the effect of octreotide on manifest diabetic renal changes, octreotide treatment was given for 3 weeks after an untreated diabetic period of 3 or 6 months. In addition, following 6 months of diabetes, a group of diabetic rats was treated with insulin for 3 weeks. Renal and glomerular hypertrophy, and increased urinary albumin excretion were observed in diabetic rats compared to non-diabetic control rats from 3 months and throughout the study period. Octreotide treatment did not affect body weight, food intake, blood glucose or serum fructosamine levels. We observed no effect of octreotide treatment on renal and glomerular hypertrophy or urinary albumin excretion compared to placebotreated diabetic rats. Insulin treatment for 3 weeks after 6 months of untreated diabetes normalized blood glucose and serum fructosamine levels, and furthermore renal hypertrophy was significantly diminished compared to the placebo-treated diabetic rats. However, insulin treatment had no effect on glomerular hypertrophy or urinary albumin excretion. In conclusion, octreotide treatment for 3 weeks following an untreated diabetic period of 3 or 6 months is unable to reduce the increased renal and glomerular volume or urinary albumin excretion. However, insulin treatment for 3 weeks with induction of euglycaemia diminishes the renal hypertrophy but has no effect on glomerular volume or urinary albumin excretion.

Abbreviations

UAE:

Urinary albumin excretion

IGF-I:

insulin-like growth factor I

IGFBP:

insulin-like growth factor binding protein

STZ:

streptozotocin

TGV:

total glomerular volume

BW:

body weight

GH:

growth hormone

RPF:

renal plasma flow

References

  1. 1.

    Mogensen CE, Andersen MJF (1973) Increased kidney size and glomerular filtration rate in early juvenile diabetes. Diabetes 22: 706–712

  2. 2.

    Seyer-Hansen K (1983) Renal hypertrophy in experimental diabetes. Kidney Int 23:641–647

  3. 3.

    Hostetter TH, Troy JL, Brenner BM (1981) Glomerular hemodynamics in experimental diabetes. Kidney Int 19: 410–415

  4. 4.

    Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin dependent patients. N Engl J Med 311: 89–93

  5. 5.

    Mogensen CE, Christensen CK, Christiansen JS, Boye N, Pedersen MM, Schmitz A (1988) Early hyperfiltration and late renal damage in insulin-dependent diabetes. Pediat Adolesc Endocr 17: 197–205

  6. 6.

    Mogensen CE (1986) Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand J Clin Lab Invest 46: 201–206

  7. 7.

    Brenner BM, Hostetter TH, Olsen JL, Rennke HG, Venkatachalam MA (1981) The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy. Acta Endocrinol (Copenh) 97: 7–10

  8. 8.

    Flyvbjerg A, Thorlacius-Ussing O, Naeraa R, Ingerslev J, Ørskov H (1988) Kidney tissue somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabetologia 31: 310–314

  9. 9.

    Flyvbjerg A, Frystyk J, Thorlacius-Ussing O, Ørskov H (1989) Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabetologia 32: 261–265

  10. 10.

    Flyvbjerg A, Frystyk J, Marshall SM (1990) Additive increase in kidney insulin-like growth factor I and initial renal enlargement in uninephrectomized-diabetic rats. Horm Metab Res 22: 516–520

  11. 11.

    Flyvbjerg A, Ørskov H (1990) Kidney tissue insulin-like growth factor I and initial renal growth in diabetic rats: relation to severity of diabetes. Acta Endocrinol (Copenh) 122: 374–378

  12. 12.

    Drop SLS, Brinkman A, Kortleve DJ, Groffen CAH, Schuller A, Zwarthoff EC (1991) The evolution of the insulin-like growth factor binding family. In: Spencer EM (ed) Modern concepts of the insulin-like growth factors, Elsevier, New York, pp 211–328

  13. 13.

    De Vroede MA, Tseng LY, Katsoyannis PG, Nissley SP, Rechler MM (1986) Modulation of insulinlike growth factor I binding to human fibroblast monolayer cultures by insulinlike growth factor carrier proteins released to the incubation media. J Clin Invest 77: 602–613

  14. 14.

    Flyvbjerg A, Kessler U, Dorka B, Funk B, Ørskov H, Kiess W (1992) Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia 35: 589–593

  15. 15.

    Flyvbjerg A, Marshall SM, Frystyk J, Hansen KW, Harris AG, Ørskov H (1992) Octreotide administration in diabetic rats: effects on renal hypertrophy and urinary albumin excretion. Kidney Int 41: 805–812

  16. 16.

    Serri O, Beauregard H, Brazeau P et al. (1991) Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 265: 888–892

  17. 17.

    Maunsbach AB (1966) The influence of different fixatives and fixation methods on the ultrastructure of the rat kidney proximal tubule cells. II. Effects of varying osmolarity, ionic strength, buffer system and fixative concentration of glutaraldehyde solution. J Ultrastruct Res 15: 283–309

  18. 18.

    Gundersen HJG (1988) The new stereological tools. APMIS 96: 379–394

  19. 19.

    Gundersen HJG (1988) The new stereological tools. APMIS 96: 857–881

  20. 20.

    Boye N, Ingerslev J (1988) Rapid and inexpensive screening microdetermination of serum fructosamine results in diabetics, uraemics, and diabetics with uraemia and healthy subjects. Scand J Clin Lab Invest 48: 779–783

  21. 21.

    Christensen CK, Ørskov C (1984) Rapid screening PEG radioimmunoassay for quantification of pathological microalbuminuria. Diabetic Nephropathy 3: 92–94

  22. 22.

    D'Ercole AJ, Stiles AD, Underwood LE (1984) Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 81: 935–939

  23. 23.

    Hossenlopp P, Seurin D, Segovia Quinson B, Hardouin S, Binoux M (1986) Analysis of serum insulin-like growth factor binding proteins using Western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 154: 138–143

  24. 24.

    Flyvbjerg A, Frystyk J, Østerby R, Ørskov H (1992) Kidney IGF-I and renal hypertrophy in GH-deficient diabetic dwarf rats. Am J Physiol 262: E956-E962

  25. 25.

    Rasch R (1979) Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment: Kidney size and glomerular volume. Diabetologia 16: 125–128

  26. 26.

    Hirschberg R, Kopple JD (1989) Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats. J Clin Invest 83: 326–330

  27. 27.

    Guler H-P, Schmid C, Zapf J, Froesch ER (1989) Effects of recombinant IGF-I on insulin-secretion and renal function in normal subjects. Proc Natl Acad Sci USA 86: 2668–2872

  28. 28.

    Parving H-H, Noer I, Mogensen CE, Svendsen P (1978) Kidney function in normal man during short-term growth hormone infusion. Acta Endocrinol Copenh 89: 796–800

  29. 29.

    Christiansen JS, Gammelgaard J, Ørskov H, Anderson A, Temler S, Parving HH (1981) Kidney function and size in normal subjects before and during growth hormone administration for one week. Eur J Clin Invest 11: 487–490

  30. 30.

    Guler H-P, Zapf J, Scheiwiller E, Froesch ER (1988) Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA 85: 4889–4893

  31. 31.

    Skottner A, Clark RG, Fryklund L, Robinson IC (1989) Growth responses in a mutant dwarf rat to human growth hormone and recombinant human insulin-like growth factor I. Endocrinology 124: 2519–2526

  32. 32.

    Mathews LS, Hammer RE, Behringer RR et al. (1988) Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 123: 2827–2833

  33. 33.

    Flyvbjerg A (1993) The role of insulin-like growth factor I in initial renal hypertrophy in experimental diabetes. In: Flyvbjerg A, Ørskov H, Alberti KGMM (eds) Growth hormone and insulin-like growth factor I in human and experimental diabetes. John Wiley & Sons, Chichester, pp 271–306

  34. 34.

    Steer KA, Sochor M, Kunjara S, Doepfner W, McLean P (1988) The effect of a somatostatin analogue (SMS 201-995) on the concentration of phosphoribosyl pyrophosphate and the activity of the pentose phosphate pathway in the early renal hypertrophy of experimental diabetes in the rat. Biochem Med Metab Biol 39: 226–233

  35. 35.

    Iwasaki S (1993) Octreotide suppresses the kidney weight and glomerular hypertrophy in diabetic rats. Nippon Jinzo Gakkai Shi 35: 247–255

  36. 36.

    Muntzel M, Hannedouche T, Niesor R et al. (1992) Longterm effects of a somatostatin analogue on renal hemodynamics and hypertrophy in diabetic rats. Clin Sci 83: 575–581

  37. 37.

    Igarashi K, Nakazawa A, Tani N, Yamazaki M, Ito S, Shibata A (1991) Effect of a somatostatin analogue (SMS 201-995) on renal function and excretion in diabetic rats. J Diabet Complications 5: 181–183

  38. 38.

    Vora J, Owens DR, Luzio SD, Atiea J, Ryder R, Hayes TM (1987) Renal response to intravenous somatostatin in insulin-dependent diabetic patients and normal subjects. J Clin Endocrinol Metab 64: 975–979

  39. 39.

    Pedersen MM, Christensen SE, Christiansen JS, Pedersen EB, Mogensen CE, Ørskov H (1990) Acute effects of a somatostatin analogue on kidney function in type 1 diabetic patients. Diabet Med 7: 304–309

  40. 40.

    Parving H-H, Christiansen JS, Noer I, Tronier B, Mogensen CE (1980) The effect of glucagon infusion on kidney function in short-term insulin-dependent juvenile diabetics. Diabetologia 19: 350–354

  41. 41.

    Johannesen J, Mons L, Kiil F (1977) Effect of glycine and glucagon on glomerular filtration and metabolic rates. Am J Physiol 233: F61-F66

  42. 42.

    Cortes P, Dulmer F, Goldman J, Levin NW (1987) Relationship between renal function and metabolic alterations in early streptozotocin-induced diabetes in rats. Diabetes 36: 80–87

  43. 43.

    Almdal TP, Vilstrup H (1988) Exogenous hyperglucagonaemia in insulin controlled diabetic rats increases urea excretion and nitrogen loss from organs. Diabetologia 31: 836–841

  44. 44.

    Krempf M, Ranganathan S, Remy JP, Charbonnel B, Guillon J (1990) Effect of a long acting somatostatin analogue (SMS 201-995) on high glomerular filtration rate in insulin dependent diabetic patients. Int J Clin Pharmacol Ther Toxicol 28: 309–311

  45. 45.

    Rasch R (1980) Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment: albumin excretion. Diabetologia 18: 413–416

  46. 46.

    Stackhouse S, Miller PL, Park SK, Meyer TW (1990) Reversal of glomerular hyperfiltration and renal hypertrophy by blood glucose normalization in diabetic rats. Diabetes 39: 989–995

  47. 47.

    Marshall SM, Alberti KGMM (1993) Alterations in the growth hormone/insulin-like growth factor I axis in human and experimental diabetes: differences and similarities. In: Flyvbjerg A, Ørskov H, Alberti KGMM (eds) Growth hormone and insulin-like growth factor I in human and experimental diabetes. John Wiley & Sons, Chichester, pp 23–46

  48. 48.

    Holly JPM (1993) Insulin-like growth binding proteins in diabetic and non-diabetic states. In: Flyvbjerg A, Ørskov H, Alberti KGMM (eds) Growth hormone and insulin-like growth factor I in human and experimental diabetes. John Wiley, Chichester, pp 47–76

Download references

Author information

Correspondence to Dr. H. GrØnbÆk.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

GrØnbÆk, H., Nielsen, B., Østerby, R. et al. Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats. Diabetologia 38, 135–144 (1995). https://doi.org/10.1007/BF00400087

Download citation

Key words

  • Diabetes mellitus
  • octreotide
  • urinary albumin excretion
  • renal hypertrophy
  • kidney morphology
  • IGF-I
  • IGFBPs
  • rat